DIABETES TECHNOLOGY & THERAPEUTICS
Volume 4, Number 5, 2002


Commentary

# Is Angiotensin I-Converting Enzyme a "Master" Disease Gene?

DAVID W. MOSKOWITZ, M.D., M.A., F.A.C.P.

## ABSTRACT

**Clustering of diseases has been appreciated by health insurers and epidemiologists for some time. Co-morbidity suggests shared pathways of disease. It is by now well agreed that common diseases have a strong genetic component. Here we present evidence that the angiotensin I-converting enzyme (ACE) deletion/deletion (*D*/*D*) genotype is associated with a large number of common adult diseases, including cardiovascular disease, cancer, and psychiatric disease. Since the ACE *D*/*D* genotype has been shown to be associated with increased levels of tissue ACE expression at the protein level, these data suggest that overactivity of ACE may be involved in the pathogenesis of many seemingly unrelated diseases. These results suggest a broad pattern of relatedness of common diseases, as well as the utility of effective ACE inhibition in their treatment and, perhaps, prevention.**

## INTRODUCTION

SINCE THE DISCOVERY of the insertion/deletion (*I*/*D*) polymorphism in the angiotensin I-converting enzyme (ACE) gene, and the demonstration in Northern European Caucasians that plasma ACE concentrations are twice as high in deletion/deletion (*D*/*D*) compared with insertion/insertion (*I*/*I*) homozygotes,[1] there has been considerable interest in its potential clinical associations. Taken altogether, however, results are conflicting as to whether the *D* allele, or the *D*/*D* genotype in particular, is significantly associated with diseases such as left ventricular hypertrophy;[2–10] ischemic or idiopathic dilated cardiomyopathy;[11,12] hypertension;[4,5,13–25] restenosis after percutaneous transluminal coronary angioplasty;[26–29] myocardial infarction;[15,30–34] coronary artery disease;[15,30,32,35–44] obesity;[5,14,19] glucose intolerance;[45,46] complications of diabetes mellitus such as nephropathy[47–53] and retinopathy;[48,50,53–55] hypertension[56] and atherosclerotic coronary artery disease;[53,57,58] progression of renal insufficiency;[59] IgA nephropathy;[60,61] sarcoidosis;[62] carotid artery thickness in normal subjects;[16,63] and stroke.[64]

The frequency of the ACE *D*/*D* genotype has been reported to vary with age,[19,65] and the strength of its association with disease may depend on gender.[31] There appears to be ethnic, and perhaps disease-associated, variability in whether or not plasma ACE concentration is correlated with ACE *I*/*D* genotype; in normal

GenoMed, Inc., St. Louis, Missouri.

Caucasians, it was,[1,14] but in a small group of normotensive African-American children,[14] and in hypertensive Japanese adults,[23] it was not.

One possible explanation for the extreme variability in results so far may be the relatively small sample sizes examined.[66] The evaluation of a single polymorphism may require a fairly large sample size ($n > 150$),[66] especially for common diseases that appear to be polygenic. If many genes are involved in the pathogenesis of a disease, then the smaller the contribution any one polymorphism is likely to make to the disease, and the larger the sample size required to avoid a type II error.

Replication also heightens the credibility of a disease association. In addition to genotyping independent samples within the same ethnic group, multiple ethnic groups can be sampled. A disease-associated genomic polymorphism that occurs in multiple ethnic groups may represent an essential step in pathogenesis.

In this study we genotyped three patient populations to assess possible clinical associations of the ACE $D/D$ genotype. Data are presented on a total of 6,414 inpatients and outpatients seen at two indigent care hospitals in St. Louis, expanding on previous data.[67] We also present results from 3,959 hemodialysis patients from the southeastern United States.

## METHODS

This study was approved by the Human Studies Committees at the St. Louis VA Medical Center ("StLVA"), St. Louis Regional Medical Center ("Regional"), and REN, a dialysis company with 40 dialysis units throughout the southeastern United States. Informed consent was not required by the Human Studies Committees since only discarded, anonymized blood samples were used.

Table 1 briefly describes the study populations. The first patient population was drawn from StLVA. It consisted of a series of 1,686 consecutive inpatients admitted to the Medical and Surgical Services of StLVA in the 3-month period from December 21, 1993 to March 31, 1994, representing 13% of annual hospital admissions; and 2,660 outpatients from the Medicine, Renal, Diabetes, Hypertension, Neurology, and Peripheral Vascular Disease Clinics

Table 1. Patient Populations

| | *WM* | *WF* | *BM* | *BF* | *HM* | *HF* | *Other* | *Totals* |
|---|---|---|---|---|---|---|---|---|
| StLVA | | | | | | | | |
| Consecutive inpatients | | | | | | | | |
| Total | 1,058 | 28 | 578 | 12 | | | 10 | 1,686 |
| No PCR product | 8 | 0 | 3 | 1 | | | | |
| Median age (years) | 65.4 | 54.9 | 64.7 | 45.8 | | | | |
| Median BMI | 26.0 | 26.2 | 24.1 | 26.9 | | | | |
| Outpatients | | | | | | | | |
| Total | 1,641 | 40 | 1,093 | 30 | | | 22 | 2,826 |
| No PCR product | 30 | 1 | 26 | 0 | | | | |
| Median age (years) | 66.6 | 53.3 | 66.2 | 45.3 | | | | |
| Median BMI | 27.5 | 27.8 | 26.7 | 27.9 | | | | |
| Regional inpatients | | | | | | | | |
| Total | 182 | 162 | 785 | 896 | | | 43 | 2,068 |
| No PCR product | 7 | 3 | 21 | 24 | | | | |
| Median age (years) | 46.4 | 49.9 | 46.3 | 53.6 | | | | |
| Median BMI | 26.5 | 29.3 | 25.0 | 29.1 | | | | |
| REN (hemodialysis patients) | | | | | | | | |
| Total | 873 | 678 | 919 | 966 | 197 | 199 | 127 | 3,959 |
| No PCR product | 24 | 15 | 31 | 26 | 2 | 1 | | |
| Median age (years) | 66.4 | 65.8 | 53.2 | 61.3 | 59.7 | 60.9 | | |
| Median BMI | 23.2 | 23.3 | 23.5 | 24.8 | 24.6 | 24.6 | | |

WM, white male; WF, white female; BM, black male; BF, black female; HM, Hispanic male; HF, Hispanic female; BMI, body mass index ($kg/m^2$).

seen between March 7, 1994 and July 26, 1995, representing 9% of the approximately 30,000 outpatients seen annually at StLVA.

The second study population consisted of 2,068 consecutive inpatients at Regional during the 5-month period from mid-April 1994 to mid-November 1994. These two hospital-based patient populations are referred to as "StL" in subsequent tables.

The third study population consisted of REN's entire population of 3,959 hemodialysis patients, whose samples were collected in March 1995. This population is referred to as "REN" in subsequent tables.

Patient charts were read and clinical data abstracted from March 1993 through March 1996 by individuals unaware of the patient's genotype. In particular, 1-year follow-up on hemodialysis patients was available, allowing identification of dialysis patients who had died in the interval since their blood sample was collected in March 1995.

Anticoagulated blood (1–5 ml) was obtained from the Hematology Laboratory of each institution after a clinician-ordered test ("complete blood count") had been performed, but before the sample was to be routinely discarded. Generally, blood samples were kept at room temperature for up to 12 h after venipuncture, and then stored at 4°C for up to 16 weeks. ACE $I/D$ genotyping was performed by someone blinded to the patient's clinical data, using the primers and conditions described by Rigat et al.[68] Since the insertion fragment (490 bp) is amplified less efficiently than the smaller deletion fragment (190 bp), 3% dimethyl sulfoxide was included,[69] as well as an *Alu* insertion-specific antisense primer, 5′ GTTTTAGCCGGGATGGTCTCGA 3′, as kindly suggested by Dr. K. Chiu. The three primers resulted in bands of 490 and 290 bp for the insertion fragment and 190 bp for the deletion fragment, and allowed unambiguous assignment of the ACE $I/D$ genotype in every case in which polymerase chain reaction (PCR) product was obtained. Approximately 3% (342 of 10,373) of samples failed to yield a PCR product. Clinical information and genotype were entered at separate times into a spreadsheet (FileMaker Pro), and unadjusted $\chi^2$ values were calculated. The level of statistical significance was taken as $p < 0.05$.

## RESULTS

To confirm our laboratory's ability to genotype a population correctly, the parents of 82 French control families [Centre d'Etudes des Polymorphismes Humaines (CEPH)] were genotyped at the ACE $I/D$ locus. The ACE $D/D$ frequency was 25.6% (42 of 164), in good agreement with other Caucasian control groups.[8,13,14,18,22,25,34,35,37]

For African-Americans, there is no agreement as to the frequency of the ACE $D/D$ genotype among control subjects. Duru et al.[13] cited a frequency close to that of American and European Caucasians (25%), but this is based on a sample size of only 37 individuals. Rutledge et al.[70] found a $D/D$ frequency of 49% among 40 control subjects. The $D/D$ frequency among African-American controls is likely to be intermediate between these two values, since the ACE $D/D$ frequency of Nigerians without dis-

Table 2. ACE *I/D* Genotyping Results: Patient "Controls"

| | *White* | *Black* | *Hispanic* |
|---|---|---|---|
| Total | 1,844 | 1,042 | 396 |
| No PCR product | 33 | 24 | 3 |
| Male | 100% | 100% | 49.7% |
| Median age (years) | 63.8 | 53.6 | 60.2 |
| Median BMI | 23.2 | 23.3 | 23.5 |
| Source | StLVA + Regional | StLVA + Regional | REN |
| *D/D* | 456 (25.2%) | 337 (33.1%) | 101 (25.7%) |
| *I/D* | 945 (52.3%) | 509 (50.0%) | 187 (47.6%) |
| *I/I* | 410 (22.7%) | 172 (16.9%) | 105 (26.7%) |

BMI, body mass index (kg/m$^2$).

Table 3. ACE *I/D* Genotyping Results of Patient Populations from Different Sources

| | *White* | | | | *Black* | | | | *Hispanic* | |
|---|---|---|---|---|---|---|---|---|---|---|
| | *Male* | | *Female* | | *Male* | | *Female* | | *Male* | *Female* |
| | *StLVA + Regional* | *REN* | *StLVA + Regional* | *REN* | *StLVA + Regional* | *REN* | *StLVA + Regional* | *REN* | *REN* | *REN* |
| Total | 2,783 | 873 | 228 | 678 | 2,377 | 919 | 949 | 966 | 197 | 199 |
| No PCR product | 58 | 24 | 4 | 15 | 57 | 31 | 25 | 28 | 2 | 1 |
| Median age (years) | 65.2 | 66.4 | 50.7 | 65.8 | 59.4 | 53.2 | 52.7 | 61.3 | 59.7 | 60.9 |
| Median BMI | 27.0 | 23.2 | 29.1 | 23.3 | 25.7 | 23.5 | 28.9 | 24.8 | 24.6 | 24.6 |
| *D/D* | 773 (28.4%)[1] | 300 (35.3%)[2] | 69 (30.8%) | 199 (30.0%)[1] | 787 (33.9%) | 337 (38.0%)[3] | 306 (33.1%) | 334 (35.6%) | 44 (22.6%) | 57 (28.8%) |
| *I/D* | 1,354 (49.7%) | 375 (44.2%) | 114 (50.9%) | 342 (51.6%) | 1,121 (48.3%) | 407 (45.8%) | 442 (47.8%) | 447 (47.7%) | 96 (49.2%) | 91 (46.0%) |
| *I/I* | 598 (21.9%) | 174 (20.5%) | 41 (18.3%) | 122 (18.4%) | 412 (17.8%) | 144 (16.2%) | 176 (19.0%) | 157 (16.7%) | 55 (28.2%) | 50 (25.3%) |

BMI, body mass index (kg/m$^2$).
[1]$p < 0.025$, [2]$p < 0.001$, [3]$p < 0.05$, compared with control group.

ease has been observed to be 35%[71] and 44% (K. Chiu, personal communication). Where it has been measured, African-Americans in urban centers such as Detroit, Oakland, and Pittsburgh have 22–26% Caucasian admixture.[72–74] If we take 35.7% as the ACE $D/D$ frequency in West African control individuals, then the "control" $D/D$ frequency of 33.1% that we arrived at (see below) would suggest 25% Caucasian admixture in our sample of St. Louis African-Americans.

Given the lack of an obvious control group, we chose to perform a disease–disease comparison, using as "control" diseases those (1) without any reported relationship to angiotensin II, (2) in which the $D/D$ frequency for Caucasians was 25%, in agreement with previous Caucasian control groups and our own laboratory's observation using European Caucasian samples, and (3) in Hardy–Weinberg equilibrium. We used the 6,414 St. Louis inpatients and outpatients for this analysis, since there is already abundant evidence for ACE's involvement in end-stage renal disease.[59–61]

The diseases that met these conditions among white males were: type 1 diabetes mellitus (IDDM; $n = 26$), cataracts in patients with type 2 diabetes (NIDDM; $n = 160$), seizure disorder ($n = 145$), peptic ulcer disease ($n = 389$), alcohol abuse ($n = 772$), gastritis ($n = 31$), eczema ($n = 20$), obesity ($n = 125$), and mean triglyceride level above 300 mg/dL ($n = 143$). This yielded a white male control group of 1,811 individuals with the following genotypes: 456 $D/D$ (25.2%), 945 $I/D$, and 410 $I/I$ (Table 2).

The genotype frequencies of white women were compared with those of the white male control group, since there is no evidence of any gender difference in $I$ and $D$ allele frequencies among healthy controls (CEPH data, not shown).

Among black men, the $D/D$ frequency varied considerably for the same nine diseases: IDDM (36.0%, $n = 25$), cataracts in patients with NIDDM (27.6%, $n = 116$), seizure disorder (36.9%, $n = 214$), peptic ulcer disease (31.7%, $n = 290$), alcohol abuse (33.1%, $n = 1{,}018$), gastritis (24.0%, $n = 50$), eczema (43.8%, $n = 16$), and mean triglyceride level above 300 mg/dL (43.8%, $n = 48$). The average $D/D$ frequency for all nine diseases was 33.1% (589 of 1,777), precisely the $D/D$ frequency for the group of 1,018 ethanol abuse patients (Table 2). Black men with alcohol abuse were therefore used as the comparison disease group ("control") for black male and female patients.

Finally, the reference $D/D$ frequency for Hispanic male and female hemodialysis patients was taken simply as the average of the group (Table 2). This is a conservative choice, since the $D/D$ frequency is elevated among white male and female and black male hemodialysis patients, and tends to be elevated among Hispanic female dialysis patients (Table 3).

The $\chi^2$ statistic was used to determine whether patients with a particular disease deviated significantly in their $D/D$ genotype frequency from the relevant "control" $D/D$ frequency. Disease–disease comparison of the frequencies of all three possible genotypes ($D/D$, $I/D$, $I/I$, with 2 degrees of freedom) almost always yielded the same results as comparison of the two genotype categories, $D/D$ and "$I/D$ plus $I/I$," with 1 degree of freedom. Thus, any disease–disease difference was due to a difference in $D/D$ frequency, rather than in $I/D$ or $I/I$ frequency.

The population frequency of the ACE $D/D$ genotype appears to vary with age. Among Caucasian centenarians, the ACE $D/D$ frequency was reported to be increased significantly above 25%.[65] However, our data contradicted this result (Table 4). White male patients 80 years or older had a $D/D$ frequency no dif-

Table 4. ACE *D/D* Frequency and Age in White and Black Men

| *Age* | *White men* | *Black men* |
|---|---|---|
| ≥80 years | | |
| Total | 140 | 177 |
| Unknown | 6 | 4 |
| *D/D* | 37 (27.6%) | 69 (39.9%) |
| *I/D* | 64 (47.8%) | 81 (46.8%) |
| *I/I* | 33 (24.6%) | 23 (13.3%) |
| <40 years | | |
| Total | 252 | 686 |
| Unknown | 3 | 17 |
| *D/D* | 78 (31.3%)[1] | 218 (32.6%) |
| *I/D* | 119 (47.8%) | 310 (46.3%) |
| *I/I* | 52 (20.9%) | 141 (21.1%) |

[1] $p < 0.05$ versus control group.

TABLE 5. ACE *D/D* ODDS RATIOS (OR): HYPERTENSION AND ITS COMPLICATIONS

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Hypertension | | | | | | | | | | | | |
| StL | 1.21[1] | 857 | 0.70 | 47 | 1.15 | 877 | 1.01 | 234 | | | | |
| LVH by echocardiography | | | | | | | | | | | | |
| StL | 1.43 | 86 | — | | 1.22 | 167 | 0.65 | 66 | | | | |
| REN | 3.0 | 10 | — | | 1.07 | 26 | 1.2 | 16 | 2.0 | 17[2] | | |
| Atrial fibrillation | | | | | | | | | | | | |
| StL | 1.24 | 78 | — | | 0.70 | 35 | 0.63 | 21 | | | | |
| REN | 1.19 | 63 | 1.67 | 50 | 1.32 | 39 | 1.26 | 39 | 2.0 | 10[2] | | |
| History of CHF | | | | | | | | | | | | |
| StL | 1.95[3] | 116 | — | | 1.13 | 164 | 0.58 | 54 | | | | |
| REN | 1.12 | 51 | 1.09 | 41 | 1.41 | 56 | 2.11[4] | 44 | 2.5 | 13[2] | | |
| Positive cardiac stress test | | | | | | | | | | | | |
| StL | 1.13 | 59 | — | | 0.79 | 33 | — | | | | | |
| Positive cardiac catheterization | | | | | | | | | | | | |
| StL | 1.20 | 67 | — | | 1.06 | 37 | — | | | | | |
| REN | 2.55[4] | 26 | 1.3 | 13 | 0.4 | 12 | 1.2 | 11 | — | — | | |
| PTCA | | | | | | | | | | | | |
| StL | 1.31 | 37 | — | | 1.4 | 16 | — | | | | | |
| CABG | | | | | | | | | | | | |
| StL | 1.95[5] | 96 | — | | 1.2 | 16 | — | | | | | |
| REN | 2.33 | 25 | 0.7 | 16 | — | | — | | — | — | | |
| Myocardial infarction | | | | | | | | | | | | |
| StL | 1.50[5] | 241 | 1.7 | 11 | 1.30 | 184 | 1.13 | 39 | | | | |
| REN | 1.76 | 38 | 0.59 | 30 | 1.01 | 33 | 0.67 | 24 | — | — | | |
| Ventricular ectopy (ventricular tachycardia or fibrillation) | | | | | | | | | | | | |
| StL | 0.9 | 13 | — | | — | | — | | | | | |
| Chronic renal failure | | | | | | | | | | | | |
| StL | 1.27 | 117 | — | | 1.08 | 175 | 0.65 | 33 | | | | |
| End-stage renal disease | | | | | | | | | | | | |
| REN | 1.18 | 221 | 1.20 | 195 | 1.07 | 415 | 1.36[1] | 256 | 1.55 | 43 | 1.52 | 29 |
| APVD (not otherwise specified) | | | | | | | | | | | | |
| StL | 1.13 | 243 | — | | 1.10 | 184 | 0.91 | 42 | | | | |
| REN | 1.86[6] | 78 | 1.01 | 63 | 0.89 | 59 | 1.66 | 51 | | | | |
| Amputation of toes or legs | | | | | | | | | | | | |
| StL | 1.9 | 13 | — | | 0.67 | 24 | — | | | | | |
| REN | 2.4 | 9 | — | | — | | — | | — | | — | |
| Revascularization of legs | | | | | | | | | | | | |
| StL | 1.19 | 35 | — | | 1.1 | 17 | — | | | | | |
| REN | 1.1 | 11 | — | | — | | — | | — | | — | |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal aortic aneurysm | | | | | | | | | | |
| StL | 1.53 | 50 | — | 1.1 | 14 | — | | | | |
| REN | 0.4 | 15 | — | 1.3 | 10 | — | | | — | — |
| Claudication | | | | | | | | | | |
| StL | 1.01 | 55 | — | 0.56 | 37 | — | | | | |
| Leg ulcer | | | | | | | | | | |
| StL | 0.3 | 13 | — | | 0.79 | 25 | — | | | |
| REN | — | | — | | — | | 0.9 | 10 | — | — |
| Transient ischemic attack | | | | | | | | | | |
| StL | 1.24 | 51 | — | | 1.19 | 27 | — | | | |
| REN | 3.0 | 10 | — | | — | | — | | — | — |
| Stroke | | | | | | | | | | |
| StL | 1.10 | 133 | — | | 1.35 | 135 | 1.12 | 28 | | |
| REN | 1.58[1] | 21 | 1.22 | 24 | 1.12 | 28 | 1.35 | 25 | — | — |
| Positive carotid Doppler | | | | | | | | | | |
| StL | 0.96 | 41 | — | | 0.2 | 10 | — | | | |
| REN | 4.5[1] | 10 | — | | — | | — | | — | — |
| Deep vein thrombosis | | | | | | | | | | |
| StL | 1.1 | 18 | — | | 1.35 | 30 | — | | | |
| Pulmonary embolism | | | | | | | | | | |
| StL | — | | — | | 2.0 | 12 | — | | | |
| Death within 1 year | | | | | | | | | | |
| REN | 1.32 | 78 | 0.82 | 60 | 1.39 | 71 | 1.42 | 63 | — | — |
| Frequent de-clotting of vascular access (in hemodialysis patients) | | | | | | | | | | |
| REN | 2.3 | 16 | 2.6 | 13 | 2.02 | 20 | 0.6 | 17 | — | |

All patients described here had hypertension but not diabetes. For sample sizes <20, the OR is given to only 2 significant figures to indicate reduced confidence.[66] Dashes indicate insufficient data. StL, patients from StLVA and Regional Hospitals; REN, hemodialysis patients; WM, white males; WF, white females; BM, black males; BF, black females; HM, Hispanic males; HF, Hispanic females; LVH, left ventricular hypertrophy; CHF, congestive heart failure; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; APVD, atherosclerotic peripheral vascular disease.

[1]$p < 0.05$, [3]$p < 0.001$, [4]$p < 0.01$, [5]$p < 0.005$, [6]$p < 0.025$ compared with control group.

[2]Pooled data for men and women combined.

ferent from the control value (27.6% vs. 25.2%), whereas white male patients under 40 years of age had a significantly higher frequency than the control value (31.3% vs. 25.2%, $p < 0.05$), suggesting that the $D/D$ genotype was associated with early mortality.

On the other hand, black male patients 80 years or older tended to have a higher $D/D$ frequency than control (39.9% vs. 33.1%, $p$ = NS), consistent with a mildly protective effect of the $D/D$ genotype. Younger black male patients had essentially the same $D/D$ frequency as the control value (32.6% vs. 33.1%).

The ACE $D/D$ frequency and odds ratio for various diseases are given in Tables 5–19. One possible reason for the observed ethnic difference in the relationship between age and ACE $D/D$ frequency may be the lower $D/D$ frequency for myocardial infarction among blacks as compared with whites (Table 8). This is the case for both hypertension (Table 5) and NIDDM (Table 6).

## DISCUSSION

Selecting the appropriate control group is critical in any case-control analysis. The most appropriate control group for a study investigating whether a genomic polymorphism might be associated with any cause of adult mortality would be the total population sampled before the onset of any significant adult mortality. Matching for age does not seem advisable when considering the ACE $I/D$ polymorphism. Unfortunately, such a control group was not available; rather, every blood sample came from a patient whose routine clinical care required at least a complete blood count.

The ACE $D/D$ genotype was hypothesized to be pleiotropic, so this study involved multiple comparisons. Since the proper statistical correction for genetic pleiotropy has not yet been established, and since this study is meant to be exploratory rather than definitive, unadjusted data are reported.

Disease–disease comparison of the frequency of each separate genotype yielded virtually identical results as the frequency of $D/D$ versus "$I/D + I/I$." This suggests that the $D/D$ genotype, rather than merely the $D$ allele, is associated with disease. Recessive behavior of the $D$ allele has been observed by other investigators,[34,75,76] and suggests that there may be a threshold effect which the $D/D$ genotype exceeds, but which the $I/D$ genotype does not. The threshold may refer to the local balance between vasoconstrictors and growth promoters on the one hand, and vasodilators and growth inhibitors on the other.[77] Perhaps sufficient vasodilator (e.g., nitric oxide, prostacyclin) is synthesized and released locally to compensate adequately for the effect of a single $D$ allele on local ACE and angiotensin II levels (a 50% increase over zero $D$ alleles),[1] but not enough vasodilator can be made to compensate fully for the larger effect of two $D$ alleles on local angiotensin II levels (a 100% increase over zero $D$ alleles).[1]

Where linkage analysis of pedigrees has been performed, none of the diseases shown in Tables 5–19 has been linked to markers near the ACE gene on chromosome 17q23. Polymorphisms that are significantly associated with a disease, however, cannot always be identified by linkage analysis of affected pedigree members.[78]

Unadjusted odds ratios are presented in Tables 5–19. The $D/D$ genotype appears to be significantly protective for very few diseases [i.e., myocardial infarction in black female patients with NIDDM, coronary artery bypass grafting in black men with NIDDM, and transmetatarsal/toe amputations in black men with NIDDM (Table 6); stage D (metastatic) prostate cancer and PSA antigen >5 in the presence or absence of prostate cancer in white men (Table 9); and carpal tunnel syndrome in black women on hemodialysis (Table 18)]. There are as yet no reports that ACE inhibition increases the incidence or severity of any of these conditions.

On the other hand, the $D/D$ genotype appears to confer susceptibility to a large number of diseases, for many of which there is already abundant evidence of the usefulness of ACE inhibition. If we limit our attention to disease categories with sample sizes of at least 20 patients, and define an odds ratio of ≥1.15 as conferring susceptibility, then many diseases are positively associated with the $D/D$ genotype (Table 20). Among large patient populations, men and women both had a similar fraction of

TABLE 6. ACE *D/D* ODDS RATIOS (OR): TYPE 2 DIABETES MELLITUS (NIDDM) AND ITS COMPLICATIONS

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| NIDDM | | | | | | | | | | | | |
| StL | 1.18 | 786 | 1.25 | 64 | 0.96 | 714 | 1.02 | 338 | | | | |
| Myocardial infarction | | | | | | | | | | | | |
| StL | 1.13 | 243 | 1.2 | 14 | 0.92 | 154 | 0.51[1] | 74 | | | | |
| REN | 0.99 | 52 | 1.34 | 29 | 1.35 | 40 | 0.99 | 58 | 1.9 | 15 | 1.2 | 10 |
| CABG | | | | | | | | | | | | |
| StL | 1.02 | 121 | 0.7 | 5 | 0.35[2] | 27 | 0.6 | 9 | | | | |
| REN | 1.92 | 28 | 1.49 | 24 | 1.0 | 18 (pooled) | 1.3 | 13 | 2.3 | 16 (pooled) | | — |
| PTCA | | | | | | | | | | | | |
| StL | 0.7 | 15 | — | | 1.3 | 10 | 1.0 | 6 | | | | |
| REN | — | | — | | (pooled w/CABG) | | 0.7 | 12 (pooled) | | (pooled w/CABG) | | — |
| Positive cardiac stress test | | | | | | | | | | | | |
| StL | 1.05 | 42 | 1.0 | 4 | 0.95 | 25 | 0.6 | 9 | | | | |
| REN | — | | — | | (pooled w/CABG) | | (pooled w/PTCA) | | | (pooled w/CABG) | | — |
| Positive cardiac catheterization | | | | | | | | | | | | |
| StL | 1.06 | 80 | — | | 1.68 | 33 | 0.3 | 16 | | | | |
| REN | 2.23[2] | 28 | 1.22 | 24 | 1.1 | 18 | 1.24 | 21 | | (pooled w/CABG) | | — |
| CHF | | | | | | | | | | | | |
| StL | 1.24 | 136 | — | | 1.39 | 140 | 0.69 | 86 | | | | |
| REN | 1.60 | 77 | 2.50[3] | 70 | 1.27 | 70 | 1.32 | 119 | 1.5 | 15 | 1.24 | 20 |
| Atrial fibrillation | | | | | | | | | | | | |
| StL | 1.20 | 59 | — | | 1.60 | 34 | 0.9 | 13 | | | | |
| REN | 2.23 | 21 | 2.12 | 24 | 3.4[1] | 16 | 1.40 | 22 | — | | — | |
| Chronic renal failure | | | | | | | | | | | | |
| StL | 1.26 | 141 | — | | 0.87 | 180 | 0.83 | 86 | | | | |
| End-stage renal disease (hemodialysis) | | | | | | | | | | | | |
| REN | 1.71[3] | 296 | 1.29 | 264 | 1.23 | 285 | 1.09 | 447 | 0.69 | 114 | 0.96 | 123 |
| APVD (not otherwise specified) | | | | | | | | | | | | |
| StL | 1.25 | 294 | 1.7 | 11 | 0.85 | 230 | 1.01 | 69 | | | | |
| REN | 2.08[3] | 119 | 1.08 | 86 | 1.16 | 104 | 1.18 | 187 | 1.86 | 23 | 0.80 | 23 |
| Transmetatarsal/toe amputation | | | | | | | | | | | | |
| StL | 2.06 | 44 | — | | 0.27[4] | 43 | — | | | | | |
| REN | 1.7 | 11 | — | | 1.4 | 15 | 1.8 | 19 | — | | — | |
| BKA | | | | | | | | | | | | |
| StL | | (pooled w/AKA) | — | | 0.67 | 32 | — | | | | | |
| REN | 3.4[1] | 15 | 3.0 | 10 | 0.79 | 25 | 1.08 | 46 | — | | — | |
| AKA | | | | | | | | | | | | |
| StL | 0.77 | 34 (pooled w/BKA) | | | 1.40 | 22 | — | | | | | |
| REN | — | | — | | — | | 1.7 | 11 | — | | — | |
| Amputation (total) | | | | | | | | | | | | |
| REN | 2.27[1] | 30 | 2.7 | 19 | 0.82 | 45 | 1.32 | 76 | | | 0.96 | 20 |

TABLE 6. ACE *D/D* ODDS RATIOS (OR): TYPE 2 DIABETES MELLITUS (NIDDM) AND ITS COMPLICATIONS (CONT'D)

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Revascularization of legs | | | | | | | | | | | | |
| StL | 1.62 | 34 | — | | 0.7 | 12 | — | | | | | |
| Abdominal aortic aneurysm | | | | | | | | | | | | |
| StL | 1.4 | 15 | — | | — | | — | | | | | |
| REN | — | | — | | — | | 8.1[2] | 5 | | | | |
| Claudication | | | | | | | | | | | | |
| StL | 1.46 | 79 | — | | 0.92 | 32 | — | | | | | |
| Leg ulcer | | | | | | | | | | | | |
| StL | 1.43 | 80 | — | | 0.98 | 86 | — | | | | | |
| REN | 2.41[1] | 38 | 0.85 | 36 | 0.65 | 41 | 1.33 | 58 | — | | — | |
| Transient ischemic attack | | | | | | | | | | | | |
| StL | 2.03 | 32 | — | | 1.4 | 17 | — | | | | | |
| REN | — | | — | | — | | 1.0 | 12 | — | | — | |
| Stroke | | | | | | | | | | | | |
| StL | 1.25 | 135 | — | | 0.96 | 118 | — | | | | | |
| REN | 2.08[2] | 34 | 0.65 | 28 | 1.89 | 31 | 1.14 | 69 | — | | — | |
| Diabetic retinopathy | | | | | | | | | | | | |
| Not otherwise specified | | | | | | | | | | | | |
| StL | 0.66 | 22 | — | | 0.89 | 23 | 1.05 | 47 | | | | |
| REN | 2.15[2] | 31 | 1.04 | 50 | 0.89 | 36 | 1.28 | 90 | 0.85 | 22 | 0.6 | 17 |
| Background | | | | | | | | | | | | |
| StL | 1.32 | 127 | — | | 1.25 | 102 | — | | | | | |
| Preproliferative | | | | | | | | | | | | |
| StL | 0.99 | 20 | — | | 1.59 | 25 | — | | | | | |
| Proliferative | | | | | | | | | | | | |
| StL | 1.55 | 35 | — | | 0.87 | 20 | — | | | | | |
| Diabetic macular edema | | | | | | | | | | | | |
| StL | 1.10 | 50 | — | | 1.07 | 29 | — | | | | | |
| Laser photocoagulation | | | | | | | | | | | | |
| StL | 1.01 | 55 | — | | 0.94 | 38 | — | | | | | |
| REN | — | | 1.9 | 13(pooled) | 1.55 | 30(pooled) | 0.88 | 33(pooled) | — | | — | |
| Cataracts | | | | | | | | | | | | |
| StL | 1.02 | 160 | — | | 0.77 | 116 | 1.14 | 36 | | | | |
| REN | 1.78 | 24 | 0.87 | 22 | 1.77 | 30 | 1.88[1] | 58 | — | | — | |
| Neuropathy | | | | | | | | | | | | |
| Not otherwise specified | | | | | | | | | | | | |
| StL | 1.10 | 63 | — | | 1.76 | 43 | 1.3 | 13 | | | | |
| REN | 2.03[2] | 32 | 0.6 | 18 | 1.2 | 19 | 0.60 | 26 | 1.78 | 21 | 1.2 | 10 |
| Feet | | | | | | | | | | | | |
| StL | 1.16 | 82 | — | | 1.04 | 59 | 0.5 | 16 | | | | |
| REN | — | | 1.3 | 13 | 0.8 | 18 | 1.23 | 37 | — | | — | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gastroparesis | | | | | | | | | | | | |
| StL | 1.6 | 17 | — | | 1.01 | 24 | 0.6 | 14 | | | | |
| REN | — | | 0.71 | 26 | 0.87 | 20 | 0.97 | 30 | — | | — | |
| Autonomic | | | | | | | | | | | | |
| StL | 2.6 | 15 | — | | 0.7 | 12 | — | | | | | |
| REN | — | | — | | — | | 1.4 | 10 | — | | — | |
| Neurogenic bladder | | | | | | | | | | | | |
| StL | 1.0 | 8 | — | | — | | — | | | | | |
| Impotence | | | | | | | | | | | | |
| StL | 0.90 | 86 | N/A | | 1.06 | 76 | N/A | | | | | |
| REN | — | | N/A | | 0.9 | 10 | N/A | | | | | |
| Deep vein thrombosis | | | | | | | | | | | | |
| StL | 2.12 | 24 | — | | 0.7 | 19 | — | | | | | |
| Pulmonary embolism | | | | | | | | | | | | |
| StL | 2.5 | 11 | — | | 7.1[4] | 9 | — | | | | | |
| Death within 1 year | | | | | | | | | | | | |
| REN | 2.29[3] | 115 | 1.07 | 83 | 1.10 | 65 | 1.24 | 92 | 1.53 | 26 | 0.92 | 29 |
| Frequent de-clotting of vascular access (hemodialysis patients) | | | | | | | | | | | | |
| REN | 1.5 | 12 | 0.8 | 14 | 1.4 | 10 | 1.71 | 24 | — | | — | |
| cf. Frequent de-clots/no NIDDM | | | | | | | | | | | | |
| REN | 2.3 | 16 | 2.6 | 13 | 2.02 | 20 | 0.6 | 17 | — | | — | |

All patients described here have NIDDM. See Table 5 for abbreviations. AKA, above-the-knee amputation; BKA, below-the-knee amputation.
[1]$p < 0.025$, [2]$p < 0.05$, [3]$p < 0.001$, [4]$p < 0.005$ compared with control group.

Table 7. ACE *D/D* Odds Ratios (OR): Type 1 Diabetes (IDDM) and Its Complications

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| IDDM | | | | | | | | | | | | |
| StL | 1.04 | 27 | — | | 1.13 | 25 | 2.57[1] | 25 | | | | |
| Retinopathy | | | | | | | | | | | | |
| StL | 0.74 | 20 | — | | 3.4 | 8 | 1.0 | 9 | | | | |
| REN | 2.43 | 20 | 1.7 | 14 | 1.3 | 13 | 1.3 | 13 | 2.3 | 9 | — | |
| Neuropathy | | | | | | | | | | | | |
| StL | 1.39 | 22 | — | | 1.2 | 8 | 2.0 | 8 | | | | |
| REN | 4.16[1] | 24 | 1.2 | 17 | 1.0 | 15 | 1.08 | 20 | — | | — | |
| APVD (not otherwise specified) | | | | | | | | | | | | |
| StL | 1.91 | 23 | — | | 2.0 | 6 | 5.1[1] | 7 | | | | |
| REN | 3.0[2] | 16 | 1.9 | 14 | 3.5[1] | 11 | 0.8 | 14 | — | | — | |
| End-stage renal disease | | | | | | | | | | | | |
| REN | 2.09[1] | 46 | 1.62 | 34 | 1.11 | 31 | 0.95 | 50 | 0.8 | 14 | 0.7 | 15 |

All of these patients have IDDM. See Table 5 for abbreviations.
[1]$p < 0.05$, [2]$p < 0.025$ compared with control group.

*D/D*-associated diseases (Table 20). Combining genders revealed three distinct population patterns (Table 21), suggesting that the ACE *D/D* genotype is associated with more diseases among Caucasians than Hispanics, and with more diseases among Hispanics than African-Americans. This is consistent with population history, in which Hispanics represent the admixture of whites, blacks, and Amerindians (who are genetically similar to Asians).

The odds ratio for hypercholesterolemia and atherosclerotic coronary artery disease is on the order of 1.7. The similar but rather unimpressive odds ratios usually seen for ACE *D/D*[66] (including this study) suggest that ACE may be one of several dozen genes involved in each disease. The larger the odds ratio, assuming an adequate sample size,[66] the more important ACE may be for causation of the disease in question, and the smaller the number of additional interacting genotypes that may exist.

Given the large number of common diseases associated with the *D/D* genotype, we hypothesize that ACE overactivity is important in their pathogenesis. That ACE inhibition can have a large clinical effect in diseases in which the ACE *D/D* odds ratio is only modestly elevated[80] suggests at least two possibilities. One is that another polymorphism within the ACE gene exists with much higher odds ratios than the *I/D* locus. This seems unlikely for two reasons. The first is that at least 17 polymorphisms, covering a region of 5.6 centiMorgans (~5–6 million bases), are in strong linkage disequilibrium with the *I/D* locus[81] (i.e., the *I* and *D* alleles represent extended haplotypes rather than a single locus). The second reason is that the ACE gene has been extensively studied for over a decade, and no more explanatory polymorphism than the *I/D* locus has been described. The possibility of there being another polymorphism within the ACE gene with a higher odds ratio for disease seems very unlikely.

The more attractive possibility is that ACE is an early rate-limiting step for multiple disease pathways (Fig. 1). The clinical effectiveness of inhibiting ACE suggests that it functions early in pathogenesis. Diseases, like the cell biological protein pathways upon which they are based, involve "cascades" of linked steps (proteins) with amplification typical of each step. The most credible way that a single drug could effectively inhibit a multistep cascade is if the target of the drug acts at a very early step in the disease pathway, before amplification steps have occurred with recruitment of many additional proteins (i.e., targets of additional drugs).

We therefore hypothesize that ACE is a "master" disease gene. Since there can only be a limited number of origins, there can be only a limited number of such susceptibility genes that are shared by many common diseases. In-

TABLE 8. ACE *D/D* ODDS RATIOS (OR): CARDIOLOGY

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Atrial fibrillation | | | | | | | | | | | | |
| StL | 1.21 | 193 | 0.9 | 9 | 1.10 | 79 | 0.67 | 40 | | | | |
| REN | 1.19 | 63 | 1.67 | 50 | 1.32 | 39 | 1.26 | 39 | 2.0 | 10[1] | | |
| Supraventricular tachycardia | | | | | | | | | | | | |
| StL | 1.40 | 25 (w/REN) | — | | 0.9 | 10 | 1.7 | 13 (w/REN) | | | | |
| REN | (pooled w/StL) | | — | | 0.4 | 13 | (pooled w/StL) | | — | | — | |
| Ventricular ectopy | | | | | | | | | | | | |
| StL | 0.95 | 33 | — | | 1.4 | 15 (w/REN) | — | | | | | |
| REN | 1.7 | 11 | 0.6 | 6 | (pooled w/StL) | | — | | — | | — | |
| Pacemaker | | | | | | | | | | | | |
| StL | 1.31 | 49 | — | | 2.0 | 16 | 1.6 | 9 | | | | |
| REN | 1.7 | 11 | 1.2 | 17 | 0.5 | 10 | 0.7 | 15 | — | | — | |
| Aortic valve replacement | | | | | | | | | | | | |
| StL | 1.49 | 21 | — | | 1.1 | 17 (w/REN) | — | | | | | |
| REN | 2.0 | 10 | — | | (pooled w/StL) | | — | | — | | — | |
| Aortic stenosis | | | | | | | | | | | | |
| StL | 0.89 | 26 | — | | 2.0 | 14 | — | | | | | |
| REN | 1.1 | 11 | — | | (pooled w/StL) | | — | | — | | — | |
| Aortic regurgitation | | | | | | | | | | | | |
| StL | 0.83 | 32 | — | | 1.74 | 26 | — | | | | | |
| REN | — | | — | | 2.0 | 2 | — | | — | | — | |
| Mitral valve replacement | | | | | | | | | | | | |
| StL | 1.9 | 13 (w/REN) | — | | 0.9 | 10 (w/REN) | — | | | | | |
| REN | (pooled w/StL) | | 2.0 | 5 | (pooled w/StL) | | — | | — | | — | |
| Mitral regurgitation | | | | | | | | | | | | |
| StL | 1.22 | 24 | — | | 0.56 | 23 | — | | | | | |
| REN | — | | 0.7 | 5 | 0.4 | 6 | — | | — | | — | |
| Mitral stenosis | | | | | | | | | | | | |
| StL | 6.0 | 3 | — | | 0.7 | 4 (w/REN) | — | | | | | |
| REN | — | | — | | (pooled w/StL) | | — | | — | | — | |
| Dilated cardiomyopathy | | | | | | | | | | | | |
| StL | 1.24 | 126 | 1.4 | 19 | 0.93 | 149 | 0.75 | 81 | | | | |
| REN | 1.83 | 76 | 1.53 | 47 | 1.08 | 69 | 1.19 | 54 | 1.2 | 10 | 1.0 | 8 |
| Death within 1 year | | | | | | | | | | | | |
| REN | 1.84[2] | 254 | 1.09 | 190 | 1.15 | 162 | 1.27 | 179 | 1.58 | 34 | 1.13 | 32 |
| Myocardial infarction | | | | | | | | | | | | |
| StL | 1.26[3] | 648 | 1.27 | 30 | 1.10 | 393 | 0.78 | 129 | | | | |
| REN | 1.21 | 107 | 1.01 | 67 | 1.10 | 79 | 0.88 | 96 | 1.45 | 24 | 1.6 | 14 |
| CHF | | | | | | | | | | | | |
| StL | 1.49[4] | 323 | 1.4 | 19 | 1.19 | 342 | 0.65 | 152 | | | | |
| REN | 1.44[5] | 156 | 1.72[2] | 128 | 1.34 | 138 | 1.37 | 183 | 1.86 | 23 | 1.31 | 32 |

TABLE 8. ACE *D/D* ODDS RATIOS (OR): CARDIOLOGY (CONT'D)

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| APVD | | | | | | | | | | | | |
| StL | 1.18 | 710 | 1.09 | 26 | 1.00 | 474 | 0.97 | 130 | | | | |
| REN | 1.87[2] | 254 | 1.25 | 176 | 1.13 | 178 | 1.24 | 256 | 1.45 | 36 | 0.89 | 34 |
| Stroke | | | | | | | | | | | | |
| StL | 1.14 | 354 | 0.9 | 18 | 1.10 | 289 | 0.82 | 97 | | | | |
| REN | 1.64[5] | 73 | 0.97 | 57 | 1.40 | 66 | 1.08 | 100 | 2.4 | 11 | 2.2 | 7 |
| Frequent de-clotting of vascular access (hemodialysis patients) | | | | | | | | | | | | |
| REN | 1.81 | 37 | 1.41 | 31 | 1.67 | 31 | 1.15 | 44 | 0.5 | 7 | 2.9 | 8 |
| Deep vein thrombosis | | | | | | | | | | | | |
| StL | 1.42 | 71 | — | | 1.14 | 61 | 1.08 | 23 | | | | |
| Pulmonary embolism | | | | | | | | | | | | |
| StL | 1.49 | 27 | — | | 3.36[6] | 24 | 0.7 | 8 | | | | |

Patients are presented without regard to whether their underlying disease is diabetes or hypertension. See Table 5 for abbreviations.
[1]Pooled data for men and women combined.
[2]$p < 0.001$, [3]$p < 0.025$, [4]$p < 0.005$, [5]$p < 0.05$, [6]$p < 0.01$.

TABLE 9. ACE *D/D* ODDS RATIOS (OR) OF COMMON CANCERS

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Lung cancer | | | | | | | | | | | | |
| StL | 1.11 | 103 | 0.4 | 8 (w/REN) | 1.79[1] | 51 | 1.2 | 16 (w/REN) | | | | |
| <50 pk-yrs | 1.4 | 16 | — | | 1.66 | 20 | — | | | | | |
| >65 pk-yrs | 0.79 | 38 | — | | 1.4 | 12 | — | | | | | |
| REN | 0.6 | 6 | (pooled w/StL) | | 0.7 | 4 | 1.3 | 18 (pooled w/StL) | — | | — | |
| Colon polyps | | | | | | | | | | | | |
| StL | 1.25 | 91 | 0.9 | 13 (w/REN) | 0.98 | 40 | 1.1 | 17 | | | | |
| REN | — | | (pooled w/StL) | | 0.3 | 16 | 0.4 | 17 | — | | — | |
| Colon cancer | | | | | | | | | | | | |
| StL | 1.25 | 81 | 0.7 | 15 (w/REN) | 1.20 | 51 | 1.35 | 20 | | | | |
| REN | 3.0 | 10 | (pooled w/StL) | | 0.9 | 10 | 1.35 | 20 | — | | — | |
| BPH | | | | | | | | | | | | |
| StL | 1.42[2] | 452 | N/A | | 1.08 | 316 | N/A | | | | | |
| REN | 1.11 | 42 | N/A | | 0.67 | 28 | N/A | | — | | N/A | |
| Transurethral resection of the prostate for BPH | | | | | | | | | | | | |
| StL | 1.74[3] | 222 | N/A | | 1.23 | 137 | N/A | | | | | |
| REN | 0.63 | 23 | N/A | | 0.7 | 8 | N/A | | — | | N/A | |
| Prostate cancer | | | | | | | | | | | | |
| StL | 1.13 | 178 | N/A | | 1.19 | 172 | N/A | | | | | |
| Stage A | — | | N/A | | 0.5 | 5 | N/A | | | | | |
| Stage B | 0.4 | 19 | N/A | | 1.85 | 23 | N/A | | | | | |
| Stage C | — | | N/A | | 0.9 | 10 | N/A | | | | | |
| Stage D | 0.13[2] | 23 | N/A | | 0.91 | 29 | N/A | | | | | |
| PSA antigen | | | | | | | | | | | | |
| <5, + prostate cancer | | | | | | | | | | | | |
| StL | 1.45 | 58 | | | 0.74 | 41 | | | | | | |
| >5, + prostate cancer | | | | | | | | | | | | |
| StL | 0.39[1] | 43 | | | 1.44 | 61 | | | | | | |
| >10, + prostate cancer | | | | | | | | | | | | |
| StL | 0.12[4] | 25 | | | 1.27 | 44 | | | | | | |
| >15, + prostate cancer | | | | | | | | | | | | |
| StL | 0.16[1] | 20 | | | 1.18 | 38 | | | | | | |
| <5, no prostate cancer | | | | | | | | | | | | |
| StL | 1.26 | 330 | | | 1.08 | 205 | | | | | | |
| >5, no prostate cancer | | | | | | | | | | | | |
| StL | 0.51[1] | 64 | | | 1.03 | 83 | | | | | | |
| >10, no prostate cancer | | | | | | | | | | | | |
| StL | 0.6 | 18 | | | 1.28 | 36 | | | | | | |
| >15, no prostate cancer | | | | | | | | | | | | |
| StL | — | | | | 1.24 | 21 | | | | | | |
| Prostate cancer | | | | | | | | | | | | |
| REN | 1.65 | 28 | N/A | | 2.3 | 15 | N/A | | — | | N/A | |

TABLE 9. ACE *D/D* ODDS RATIOS (OR) OF COMMON CANCERS

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Skin cancer (not otherwise specified) | | | | | | | | | | | | |
| StL | 1.35 | 115 | 0.4 | 16 (w/REN) | — | | — | | | | | |
| REN | 1.5 | 9 | (pooled w/StL) | | — | | — | | — | | — | |
| Melanoma (StL + REN) | 0.7 | 10 | 3.0 | 2 | — | | — | | — | | — | |
| Basal cell cancer | | | | | | | | | | | | |
| StL | 2.36[2] | 52 | — | | — | | — | | | | | |
| REN | 6.0 | 3 | 1.5 | 6 | — | | — | | 1.4 | 2[5] | | |
| Pancreatic cancer | 2.0 | 10 | (StL + REN pooled)[5] | | 2.1 | 8 | (StL + REN pooled)[5] | | | | | |
| Liver cancer | 1.5 | 3 | (StL + REN pooled)[5] | | 8.1[4] | 5 | (StL + REN pooled)[5] | | | | | |
| Multiple myeloma | 1.5 | 12 | (StL + REN pooled)[5] | | 1.24 | 21 | (StL + REN pooled)[5] | | | | | |
| Myelodysplastic syndrome | | | | | | | | | | | | |
| StL | 4.0 | 7[5] | | | — | | — | | — | | — | |
| Lymphoma (total) | 1.58 | 23 | (StL + REN pooled)[5] | | 0.9 | 10 | (StL + REN pooled)[5] | | — | | — | |
| Non-Hodgkin's lymphoma | 1.7 | 14 | (StL + REN pooled)[5] | | — | | — | | — | | — | |
| Hodgkin's lymphoma | 1.2 | 7 | (StL + REN pooled)[5] | | — | | — | | — | | — | |
| Renal cell cancer | | | | | | | | | | | | |
| StL | 1.57 | 26 | — | | 1.7 | 13 | 1.2 | 8 (w/REN) | | | | |
| REN | 2.6 | 15 | 1.1 | 11 | 0.5 | 15 | (pooled w/StL) | | | | | |
| Ear-nose-throat cancer | | | | | | | | | | | | |
| StL | 1.32 | 65 | — | | 1.56 | 39 | 1.0 | 9 | | | | |
| <50 pk-yr | 0.3 | 11 | — | | 1.0 | 15 | | | | | | |
| >65 pk-yrs | 1.49 | 21 | — | | 5.0[1] | 7 | (>50 pk-yr) | | | | | |
| Bladder cancer | | | | | | | | | | | | |
| StL | 2.15[2] | 62 | — | | 0.7 | 12 | 0.7 | 4 (w/REN) | | | | |
| <50 pk-yr | 0.6 | 12 | — | | | | | | | | | |
| >65 pk-yrs | 1.9 | 13 | — | | | | | | | | | |
| REN | 1.8 | 8 | — | | | | | | | | | |
| Leukemia | 1.58 | 23 | (StL + REN pooled)[5] | | 2.4 | 11 | (StL + REN pooled)[5] | | | | | |
| Chroic leukemia | | | | | | | | | | | | |
| CML + CLL | 1.98 | 20 | (StL + REN pooled)[5] | | 4.0 | 9 | (StL + REN pooled)[5] | | | | | |
| CLL | 3.6[1] | 11 | (StL + REN pooled)[5] | | | | | | | | | |
| Fibrocystic breast disease | | | | | | | | | | | | |
| StL | | | 1.0 | 4 | | | 1.6 | 9 | | | | |
| Breast cancer | | | | | | | | | | | | |
| StL | | | 0.2 | 16 | | | 0.93 | 51 | | | | |
| REN | | | 1.2 | 14 | | | 0.56 | 23 | | | | |
| Cervical cancer | N/A | | 0.6 | 6 (StL + REN pooled) | | | 2.4 | 16 (StL + REN pooled) | | | | |
| Esophageal cancer | | | | | | | | | | | | |
| StL | 8.9[2] | 8 | — | | 0.6 | 14[5] | | | | | | |
| Uterine fibroids | | | | | | | | | | | | |
| StL | N/A | | — | | N/A | | 0.81 | 35 | N/A | | — | |

See Table 5 for abbreviations. BPH, benign prostatic hyperplasia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; pk-yr, pack years of cigarettes smoked; N/A, not applicable.

[1]$p < 0.05$, [2]$p < 0.005$, [3]$p < 0.001$, [4]$p < 0.025$.

[5]Pooled data for men and women combined.

TABLE 10. ACE *D/D* ODDS RATIOS (OR) OF PULMONARY DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| COPD | | | | | | | | | | | | |
| StL | 1.29[1] | 645 | 1.24 | 34 | 1.01 | 292 | 0.88 | 79 | | | | |
| <50 pk-yr | 1.09 | 153 | 0.7 | 11 (w/REN) | 0.90 | 94 | 1.32 | 38 | | | | |
| >50 pk-yr | 1.42[1] | 229 | 0.5 | 13 | 1.08 | 80 | 0.9 | 13 | | | | |
| REN | 1.66 | 67 | 0.48 | 38 | 0.74 | 45 | 1.31 | 28 | 1.5 | 9[2] | | |
| Asthma | | | | | | | | | | | | |
| StL | 0.74 | 55 | 1.72 | 30 | 0.97 | 93 | 0.82 | 125 | | | | |
| REN | 3.6[3] | 11 | 0.8 | 14 | 1.3 | 18 | 1.19 | 27 | 0.5 | 7[2] | | |
| Pulmonary hypertension | | | | | | | | | | | | |
| StL | 1.39 | 22 | 1.0 | 8 (w/REN) | 1.08 | 20 | — | | | | | |
| REN | 1.2 | 7 | (pooled w/StL) | | 0.5 | 10 | 1.4 | 15 | — | | — | |
| Obstructive sleep apnea | | | | | | | | | | | | |
| StL | 0.93 | 67 | 1.2 | 7 (w/REN) | 1.01 | 33 | 0.7 | 12 | | | | |
| Cigarette abuse | | | | | | | | | | | | |
| <1 ppd | | | | | | | | | | | | |
| StL | 1.38 | 60 | 2.4 | 9 (w/REN) | 0.98 | 227 | 0.96 | 103 | | | | |
| REN | 3.0 | 4 | (pooled w/StL) | | — | | — | | — | | — | |
| >1 ppd | | | | | | | | | | | | |
| StL | 1.33 | 623 | 0.99 | 44 | 1.04 | 266 | 1.43 | 53 | | | | |
| REN | 1.5 | 9 | — | | — | | — | | — | | — | |
| <30 pk-yr | | | | | | | | | | | | |
| StL | 1.04 | 350 | 1.55 | 35 | 1.03 | 544 | 1.02 | 206 | | | | |
| REN | 2.5 | 11 | — | | — | | — | | — | | — | |
| >30 pk-yr | | | | | | | | | | | | |
| StL | 1.25 | 748 | 1.21 | 45 | 1.01 | 442 | 0.86 | 94 | | | | |
| >50 pk-yr | | | | | | | | | | | | |
| StL | 1.43 | 489 | 1.05 | 23 | 0.96 | 209 | 0.95 | 25 | | | | |
| >75 pk-yr | | | | | | | | | | | | |
| StL | 1.43 | 295 | — | | 1.27 | 83 | — | | | | | |
| >100 pk-yr | | | | | | | | | | | | |
| StL | 1.35 | 109 | — | | 1.13 | 25 | — | | | | | |
| >125 pk-yr | | | | | | | | | | | | |
| StL | 1.32 | 52 | — | | 0.9 | 10 | — | | | | | |
| Deep vein thrombosis | | | | | | | | | | | | |
| StL | 1.42 | 71 | 0.3 | 10 (w/REN) | 1.14 | 61 | 1.08 | 23 | | | | |
| Pulmonary embolism | | | | | | | | | | | | |
| StL | 1.49 | 27 | — | | 3.36[4] | 24 | 0.6 | 13 (w/REN) | | | | |

See Table 5 for abbreviations. COPD, chronic obstructive pulmonary disease; pk-yr, pack-years of cigarettes smoked; ppd, packs per day.
[1]$p < 0.025$; [3]$p < 0.05$, [4]$p < 0.005$.
[2]Pooled data for men and women combined.

TABLE 11. ACE *D/D* ODDS RATIOS (OR) OF ENDOCRINOLOGIC DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Gout | | | | | | | | | | | | |
| StL | 1.39 | 141 | — | | 0.77 | 195 | 1.35 | 25 | | | | |
| REN | 1.59 | 43 | 4.0[1] | 14 | 0.93 | 54 | 1.21 | 40 | 0.9 | 17[2] | | |
| Hypothyroidism | | | | | | | | | | | | |
| StL | 0.89 | 39 | 0.6 | 19 | 1.71 | 24 | 0.6 | 23 | | | | |
| REN | — | | 2.2 | 19 | — | | 2.0 | 14 | — | | — | |
| Obesity | | | | | | | | | | | | |
| StL | 1.02 | 125 | 0.6 | 19 | 0.97 | 102 | 1.01 | 59 | | | | |
| REN | 0.6 | 6 | — | | 0.8 | 7 | 1.01 | 21 | — | | — | |
| BMI | | | | | | | | | | | | |
| >35 | | | | | | | | | | | | |
| StL | 1.18 | 228 | 1.30 | 56 | 1.15 | 182 | 1.06 | 201 | | | | |
| REN | 1.40 | 25 | 1.43 | 43 | 0.91 | 42 | 1.08 | 72 | — | | — | |
| >30 | | | | | | | | | | | | |
| StL | 1.13 | 702 | 1.73[3] | 88 | 1.04 | 502 | 1.04 | 343 | | | | |
| REN | 1.33 | 71 | 1.29 | 99 | 1.27 | 124 | 1.08 | 192 | — | | — | |
| <20 | | | | | | | | | | | | |
| StL | 0.95 | 202 | 1.1 | 18 | 1.26 | 271 | 0.83 | 79 | | | | |
| REN | 1.64[1] | 132 | 1.57[1] | 156 | 1.16 | 175 | 1.01 | 150 | — | | — | |
| Cholesterol | | | | | | | | | | | | |
| >200 mg/dL | | | | | | | | | | | | |
| StL | 1.14 | 767 | 1.22 | 62 | 1.03 | 602 | 0.89 | 273 | | | | |
| REN | 1.72[4] | 128 | 1.59[4] | 195 | 1.05 | 112 | 0.93 | 254 | 1.53 | 26 | 1.09 | 51 |
| <200 mg/dL | | | | | | | | | | | | |
| StL | 1.21 | 751 | 1.07 | 65 | 1.03 | 738 | 1.06 | 256 | | | | |
| REN | 1.59[5] | 702 | 1.15 | 447 | 1.27[1] | 758 | 1.20 | 670 | 0.73 | 168 | 1.21 | 142 |
| <150 mg/dL | | | | | | | | | | | | |
| StL | 1.17 | 232 | 0.57 | 25 | 1.25 | 286 | 1.20 | 94 | | | | |
| REN | 1.76[5] | 315 | 1.25 | 152 | 1.25 | 361 | 1.17 | 204 | 0.55 | 81 | 0.57 | 55 |
| >250 mg/dL, triglycerides >300 mg/dL (mixed hyperlipidemia) | | | | | | | | | | | | |
| StL | 0.80 | 61 | 1.2 | 7 | 1.8 | 19 | 2.0 | 10 | | | | |
| REN | 0.2 | 14 | 1.75 | 27 | 3.2[3] | 18 | 0.9 | 16 | — | | 1.2 | 7 |
| <150 mg/dL, triglycerides <150 mg/dL | | | | | | | | | | | | |
| StL | 1.53 | 47 | 0.6 | 19 | 1.12 | 143 | 1.03 | 80 | | | | |
| REN | 1.70[5] | 242 | 1.15 | 111 | 1.18 | 295 | 1.17 | 161 | 0.51 | 53 | 0.62 | 34 |
| Triglycerides | | | | | | | | | | | | |
| >300 mg/dL | | | | | | | | | | | | |
| StL | 1.00 | 143 | 1.0 | 8 | 1.57 | 48 | 1.8 | 7 | | | | |
| REN | 1.55[6] | 99 | 1.12 | 84 | 2.33[3] | 28 | 1.19 | 54 | — | | — | |
| >250 mg/dL | | | | | | | | | | | | |
| StL | 0.96 | 180 | 2.0 | 15 | 1.36 | 82 | 1.12 | 28 | | | | |
| REN | 1.73[4] | 144 | 1.04 | 131 | 1.88[3] | 58 | 1.40 | 93 | — | | — | |
| >200 mg/dL | | | | | | | | | | | | |
| StL | 1.09 | 253 | 1.58 | 23 | 1.12 | 126 | 1.16 | 71 | | | | |
| REN | 1.62[5] | 230 | 1.14 | 223 | 1.41 | 124 | 1.39 | 174 | — | | — | |
| <200 mg/dL | | | | | | | | | | | | |
| StL | 1.39[3] | 290 | 1.08 | 80 | 1.08 | 560 | 0.93 | 433 | | | | |
| REN | 1.64[5] | 607 | 1.34[3] | 427 | 1.20[6] | 754 | 1.07 | 757 | — | | — | |
| <150 mg/dL | | | | | | | | | | | | |
| StL | 1.37 | 194 | 0.95 | 59 | 1.05 | 454 | 0.94 | 364 | | | | |
| REN | 1.58[5] | 466 | 1.12 | 282 | 1.11 | 595 | 1.09 | 615 | — | | — | |
| Hyperparathyroidism | | | | | | | | | | | | |
| Primary StL | 1.2 | 7 | — | | 0.6 | 13 | — | | | | | |
| Tertiary REN | 1.0 | 8 | 0.9 | 9 | 2.4 | 11 | 0.7 | 8 | — | | — | |
| Renal osteodystrophy | | | | | | | | | | | | |
| REN | 0.7 | 5 | 0.3 | 12 | 1.1 | 17 | 0.5 | 10 | — | | — | |
| Paget's disease | | | | | | | | | | | | |
| StL | — | | — | | 1.5 | 7 | — | | | | | |
| Osteoporosis | | | | | | | | | | | | |
| StL | 0.3 | 10 | 2.0 | 5 (w/REN) | — | | 2.0 | 5 (w/REN) | — | | — | |

See Table 5 for abbreviations. BMI, body mass index (kg/m$^2$).
[1]$p < 0.01$, [3]$p < 0.025$, [4]$p < 0.005$, [5]$p < 0.001$, [6]$p < 0.05$.
[2]Pooled data for men and women combined.

TABLE 12. ACE *D/D* ODDS RATIOS (OR) OF GASTROENTEROLOGIC DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Alcoholic hepatitis | | | | | | | | | | | | |
| StL | 0.90 | 60 | — | | 0.81 | 84 | 1.4 | 12 | | | | |
| REN | — | | — | | 0.5 | 5 | — | | — | | — | |
| Alcoholic cirrhosis | | | | | | | | | | | | |
| StL | 0.94 | 83 | 1.5 | 3 (w/REN) | 1.07 | 84 | 1.8 | 15 | | | | |
| Alcoholic pancreatitis | | | | | | | | | | | | |
| StL | 0.74 | 45 | — | | 0.94 | 60 | 1.2 | 19 | | | | |
| REN | — | | 2.1 | 12 | — | | 1.52 | 28 | — | | — | |
| Esophageal varices | | | | | | | | | | | | |
| StL | 0.6 | 18 | — | | 0.5 | 15 | 2.0 | 4 | | | | |
| Ascites (and alcoholic cirrhosis) | | | | | | | | | | | | |
| StL | 0.3 | 11 | — | | 1.7 | 13 | 1.2 | 8 | | | | |
| Gastro-esophageal reflux disease | | | | | | | | | | | | |
| StL | 1.50[1] | 191 | 1.27 | 20 (w/REN) | 0.94 | 85 | 0.87 | 30 | | | | |
| REN | 0.9 | 13 | | (pooled w/StL) | 2.3 | 17 | 1.6 | 16 | — | | 1.9 | 5 |
| Hiatal hernia | | | | | | | | | | | | |
| StL | 1.17 | 166 | 1.3 | 10 | 0.81 | 56 | 0.60 | 26 | | | | |
| REN | 2.0 | 15 | 2.4 | 9 | 2.0 | 10 | 0.67 | 20 | — | | — | |
| Peptic ulcer disease | | | | | | | | | | | | |
| StL | 0.98 | 382 | 0.99 | 24 | 0.94 | 290 | 0.77 | 80 | | | | |
| REN | 1.38 | 63 | 0.79 | 38 | 0.87 | 63 | 1.59 | 50 | 1.3 | 13 | 0.6 | 6 |
| Esophagitis | | | | | | | | | | | | |
| StL | 1.27 | 20 | — | | 0.7 | 12 | — | | | | | |
| REN | 0.5 | 7 | — | | — | | 0.4 | 6 | — | | — | |
| Gastritis | | | | | | | | | | | | |
| StL | 1.03 | 31 | 1.1 | 15 (w/REN) | 0.64 | 50 | 1.08 | 20 | | | | |
| REN | 1.5 | 18 | 0.9 | 9 | 1.1 | 14 | 1.15 | 22 | — | | — | |
| Cholecystectomy | | | | | | | | | | | | |
| StL | 1.13 | 149 | 1.27 | 40 | 0.99 | 55 | 1.94[1] | 53 | | | | |
| REN | 2.14[1] | 43 | 1.53 | 50 | 0.8 | 17 | 1.14 | 47 | 1.0 | 4 | 0.4 | 8 |
| Diverticulosis | | | | | | | | | | | | |
| StL | 0.44[2] | 62 | — | | 0.69 | 47 | 1.1 | 14 | | | | |
| REN | 1.30 | 23 | 2.06 | 22 | 1.4 | 17 | 1.64 | 29 | — | | — | |
| Diverticulitis | | | | | | | | | | | | |
| StL | 2.4 | 18 | — | | 0.7 | 8 | 1.6 | 9 | | | | |
| REN | 1.0 | 4 | — | | — | | — | | — | | — | |
| Irritable bowel syndrome | | | | | | | | | | | | |
| StL | 2.3 | 14 | 1.0 | 4 (w/REN) | 4.0 | 3 | 2.0 | 2 | | | | |
| Inflammatory bowel disease | | | | | | | | | | | | |
| StL | 1.3 | 13 | 2.2 | 7 (w/REN) | 1.2 | 8 | 1.4 | 5 | | | | |
| REN | 1.8 | 8 | | (pooled w/StL) | — | | — | | — | | — | |

TABLE 12. ACE *D/D* ODDS RATIOS (OR) OF GASTROENTEROLOGIC DISEASES (CONT'D)

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Inguinal hernia repair | | | | | | | | | | | | |
| StL | 1.44[1] | 46 | 3.0 | 4 (w/REN) | 2.0 | 16 | — | | | | | |
| Viral hepatitis A | | | | | | | | | | | | |
| StL | 5.2[3] | 11 | — | | 0.9 | 16 | 0.5 | 5 | | | | |
| REN | — | | — | | 0.8 | 7 | — | | — | | — | |
| Viral hepatitis B | | | | | | | | | | | | |
| StL | 1.39 | 22 | — | | 1.08 | 40 | 0.5 | 11 | | | | |
| REN | 1.5 | 6 | — | | 2.0 | 18 | 1.0 | 12 | — | | — | |
| Viral hepatitis C | | | | | | | | | | | | |
| StL | 0.52 | 40 | — | | 1.05 | 91 | 0.5 | 15 | | | | |
| REN | 1.3 | 10 | — | | 1.35 | 45 | 2.7 | 14 | — | | — | |

See Table 5 for abbreviations.
[1]$p < 0.025$, [2]$p < 0.05$, [3]$p < 0.005$.

TABLE 13. ACE *D/D* ODDS RATIOS (OR) OF NEUROLOGIC DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Alzheimer's disease | | | | | | | | | | | | |
| StL | 0.52 | 20 | — | | 1.5 | 14 | 1.4 | 10 (w/REN) | | | | |
| Multi-infarct dementia | | | | | | | | | | | | |
| StL | 1.72 | 30 | — | | 0.94 | 41 | 2.0 | 8 (w/REN) | | | | |
| REN | — | | — | | 1.4 | 5 | (pooled w/StL) | | — | | — | |
| Dementia (not otherwise specified) | | | | | | | | | | | | |
| StL | 0.87 | 44 | — | | 1.32 | 48 | 2.8 | 12 | | | | |
| REN | 3.4[1] | 15 | 0.7 | 5 | 1.0 | 12 | 1.3 | 18 | — | | — | |
| Parkinson's disease | | | | | | | | | | | | |
| StL | 1.05 | 42 | 3.0 | 6 (w/REN) | 2.3 | 17 | 1.6 | 9 (w/REN) | | | | |
| REN | 5.9[2] | 9 | (pooled w/StL) | | 1.4 | 5 | (pooled w/StL) | | — | | — | |
| Multiple sclerosis | | | | | | | | | | | | |
| StL | 1.9 | 13 | — | | 8.2[1] | 5 | 1.0 | 6 (w/REN) | | | | |
| Migraine headaches | | | | | | | | | | | | |
| StL | 0.6 | 18 | 1.2 | 7 (w/REN) | 0.7 | 15 | 1.2 | 16 | | | | |
| Headaches (not migrainous) | | | | | | | | | | | | |
| StL | 1.2 | 14 | — | | 1.52 | 21 | 1.3 | 13 | | | | |
| Seizure disorder | | | | | | | | | | | | |
| StL | 1.02 | 145 | 1.3 | 10 | 1.18 | 214 | 1.33 | 63 | | | | |
| REN | 1.98 | 25 | 0.59 | 30 | 0.95 | 44 | 0.94 | 60 | 1.2 10[3] | | | |
| Hearing loss | | | | | | | | | | | | |
| StL | 2.6[4] | 17 (w/REN) | — | | 5.0[4] | 7 (w/REN) | — | | | | | |

See Table 5 for abbreviations.
[1]$p < 0.025$, [2]$p < 0.005$, [4]$p < 0.05$.
[3]Pooled data for men and women combined.

TABLE 14. ACE *D/D* ODDS RATIOS (OR) OF PSYCHIATRIC DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Bipolar affective disorder | | | | | | | | | | | | |
| StL | 2.85[1] | 49 | 1.2 | 7 (w/REN) | 1.4 | 15 (w/REN) | 0.3 | 8 (w/REN) | | | | |
| Schizophrenia | | | | | | | | | | | | |
| StL | 1.27 | 87 | — | | 0.89 | 85 | 0.8 | 11 (w/REN) | | | | |
| Depression | | | | | | | | | | | | |
| StL | 1.22 | 343 | 1.62 | 34 | 0.90 | 176 | 0.89 | 85 | | | | |
| REN | 1.61 | 54 | 0.97 | 53 | 1.35 | 30 | 1.95[2] | 57 | — | | — | |
| Anxiety | | | | | | | | | | | | |
| StL | 1.10 | 96 | 0.9 | 17 (w/REN) | 0.7 | 20 (w/REN) | 0.9 | 19 (w/REN) | | | | |
| Drug abuse | | | | | | | | | | | | |
| Not otherwise specified | | | | | | | | | | | | |
| StL | 0.71 | 26 | 4.0 | 7 (w/REN) | 0.83 | 55 | 0.6 | 9 (w/REN) | | | | |
| REN | 2.1 | 12 | (pooled w/StL) | | 1.01 | 27 | 1.84 | 20 (all REN drug abuse pooled) | | | | |
| Cocaine | | | | | | | | | | | | |
| StL | 1.03 | 62 | 1.8 | 8 | 1.08 | 290 | 0.90 | 62 | | | | |
| REN | — | | — | | 1.85 | 46 | 1.7 | 11 | — | | — | |
| Heroin | | | | | | | | | | | | |
| StL | 1.19 | 28 | 4.0 | 7 | 1.23 | 119 | 0.59 | 22 | | | | |
| REN | — | | — | | 8.1[1] | 15 | — | | | | | |
| Marijuana | | | | | | | | | | | | |
| StL | 1.52 | 65 | 1.5 | 6 | 0.98 | 144 | 0.89 | 36 | | | | |
| REN | — | | — | | 1.2 | 8 | — | | | | | |
| Alcohol abuse | | | | | | | | | | | | |
| StL | 1.01 | 774 | 1.24 | 34 | 1.00 | 1,018 | 1.00 | 148 | | | | |
| REN | 1.49 | 21 | — | | 1.06 | 67 | 0.77 | 29 | — | | — | |

See Table 5 for abbreviations.
[1]$p < 0.001$, [2]$p < 0.025$.

TABLE 15. ACE *D/D* ODDS RATIOS (OR) OF RENAL DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Kidney stones | | | | | | | | | | | | |
| StL | 1.16 | 64 | 2.2 | 14 (w/REN) | 1.52 | 21 | 2.0 | 8 (w/REN) | | | | |
| REN | 1.3 | 10 | (pooled w/StL) | | — | | (pooled w/StL) | | — | | — | |
| Membranous glomerulonephritis | | | | | | | | | | | | |
| StL + REN | 0.8 | 14 | 4.0 | 7 | 0.9 | 19 | 3.1 | 5 | — | | — | |
| IgA glomerulonephritis | | | | | | | | | | | | |
| StL + REN | 2.1 | 12 | 4.0 | 7 | >5 | 3 | 1.0 | 3 | — | | — | |
| Obstructive uropathy | | | | | | | | | | | | |
| StL + REN | 1.98 | 25 | 1.0 | 4 | 0.76 | 22 | — | | — | | — | |
| Acquired renal cystic disease | | | | | | | | | | | | |
| REN | — | | 0.4 | 9 | 2.5 | 18 | 1.6 | 9 | 4.3 | 5[1] | | |
| Membranoproliferative glomerulonephritis | | | | | | | | | | | | |
| StL + REN | 1.5 | 3 | 3.0 | 4 | 1.4 | 5 | — | | — | | — | |
| Amyloidosis | | | | | | | | | | | | |
| StL + REN | 1.0 | 4 | — | | — | | — | | — | | — | |
| Autosomal dominant polycystic kidney disease | | | | | | | | | | | | |
| StL + REN | 1.25 | 27 | — | | 1.0 | 6 | — | | — | | — | |
| Systemic lupus erythematosus | | | | | | | | | | | | |
| StL | 0.7 | 5 (w/REN) | — | | 1.0 | 9 (w/REN) | 2.0 | 8 | | | | |
| REN | (pooled w/StL) | | 1.91 | 23 | (pooled w/StL) | | 1.01 | 42 | 1.4 | 6[1] | | |
| Focal segmental glomerulosclerosis | | | | | | | | | | | | |
| StL | 1.04 | 27 (w/REN) | — | | 2.0 | 18 | — | | | | | |
| REN | (pooled w/StL) | | 1.5 | 12 | 1.12 | 28 | 0.6 | 31 | 1.2 | 7[1] | | |
| HIV-associated nephropathy | | | | | | | | | | | | |
| StL | — | | — | | 0.8 | 7 | — | | | | | |
| REN | — | | — | | 2.49[2] | 29 | 2.0 | 8 | — | | — | |

See Table 5 for abbreviations.
[1]Pooled data for men and women combined.
[2]$p < 0.025$.

TABLE 16. ACE *D/D* ODDS RATIOS OF OPHTHALMOLOGIC DISEASES

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Cararacts | | | | | | | | | | | | |
| Total | | | | | | | | | | | | |
| StL | 1.14[1] | 353 | 3.5[2] | 13 | 0.95 | 228 | 1.08 | 46 | | | | |
| REN | 1.31 | 49 | 1.29 | 45 | 1.46 | 50 | 1.89[3] | 93 | 1.0 | 12 | 1.9 | 10 |
| In patients with NIDDM | | | | | | | | | | | | |
| StL | 1.02 | 160 | 3.0 | 6 | 0.77 | 116 | 1.14 | 36 | | | | |
| REN | 1.78 | 24 | 0.87 | 22 | 1.77 | 30 | 1.88[2] | 58 | 1.1 | 11 | 1.9 | 10 |
| In patients without NIDDM | | | | | | | | | | | | |
| StL | 1.26 | 191 | 4.0 | 7 | 1.18 | 111 | 0.3 | 7 | | | | |
| REN | 0.66 | 22 | 1.98 | 20 | 1.1 | 17 | 2.29[2] | 32 | — | | — | |
| Glaucoma | | | | | | | | | | | | |
| StL | 1.56[1] | 119 | 0.8 | 14 (w/REN) | 1.13 | 186 | 1.08 | 40 | | | | |
| REN | 2.0 | 10 | (pooled w/StL) | | 1.2 | 16 | 0.9 | 16 | 1.0 | 4[4] | | |

See Table 5 for abbreviations.
[1]$p < 0.05$, [2]$p < 0.025$, [3]$p < 0.005$.
[4]Pooled data for men and women combined.

Table 17. ACE *D/D* Odds Ratios (OR) of Allergic, Immunologic, and Infectious Diseases

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Allergy to penicillin or sulfa | | | | | | | | | | | | |
| StL | 3.3[1] | 17 | — | | 0.8 | 7 | — | | | | | |
| Allergic sinusitis | | | | | | | | | | | | |
| StL | 1.86[2] | 52 | — | | 1.17 | 30 | 0.8 | 11 | | | | |
| Allergic rhinitis | | | | | | | | | | | | |
| StL | 0.9 | 17 | 6.0 | 3 | 1.4 | 5 | 0.8 | 7 | | | | |
| HIV | | | | | | | | | | | | |
| StL | 1.6 | 17 | — | | 1.35 | 50 | 3.0 | 10 | | | | |
| REN | — | | — | | 2.59[3] | 33 | 2.0 | 8 | — | | — | |
| AIDS | | | | | | | | | | | | |
| StL | 0.9 | 9 | — | | 1.26 | 26 | 1.5 | 7 (w/REN) | | | | |
| REN | — | | — | | 8.1[4] | 15 | (pooled w/StL) | | — | | — | |
| Tuberculosis | | | | | | | | | | | | |
| StL | 1.13 | 29 | — | | 1.68 | 44 | 1.4 | 5 | | | | |
| Pelvic inflammatory disease | | | | | | | | | | | | |
| StL | N/A | | — | | N/A | | 1.2 | 11 | | | | |

See Table 5 for abbreviations. N/A, not applicable.
[1]$p < 0.01$, [2]$p < 0.05$, [3]$p < 0.005$, [4]$p < 0.001$.

dividual diseases are likely to be distinguished by additional genetic polymorphisms that confer organ specificity; these remain to be determined.

Since ACE inhibitors have superior, although not yet fully explained, clinical efficacy, and an established safety profile, our data suggest many additional disease targets for the therapeutic use of ACE inhibitors. Furthermore, since the ACE *D/D*-associated diseases described here are largely age-dependent, it may be possible to lower all-cause morbidity and even mortality, especially for individuals with the ACE *D/D* genotype, by the early, perhaps even presymptomatic, administration of an ACE inhibitor. Whether ACE inhibition increases the incidence or severity of diseases with a "protective" *D/D* odds ratio (e.g., $\leq 0.60$) remains to be seen. On balance, however, more good than harm seems likely to come from ACE inhibition at the population level (Table 21).

## ACKNOWLEDGMENTS

This project was made possible by the skill and dedication of Wei Liu (DNA preparation, genotyping, data entry), Yvonne C. Hill (chart review), and Sally S. Anderson (chart review). Scott Wegleitner (St. Louis VA Medical Center Hematology Laboratory), Gene Palombo (custom design of FileMaker Pro database), and Barbara Maurice (St. Louis VA Medical Center Medical Records) went out of their way to be helpful. Emily Masterson and Rebecca Skomal kindly helped with genotyping, and Tonia Willekes, M.D. and Karen Martin, R.N. with chart review.

Table 18. ACE *D/D* Odds Ratios (OR) of Rheumatologic and Orthopedic Diseases

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Systemic lupus erythematosus | | | | | | | | | | | | |
| StL | 0.7 | 6 (w/REN) | 1.0 | 4 | 1.2 | 8 (w/REN) | 1.6 | 18 | | | | |
| REN | (pooled w/StL) | | 1.91 | 23 | (pooled w/REN) | | 0.92 | 42 | 1.0 | 6[1] | | |
| Rheumatoid arthritis | | | | | | | | | | | | |
| StL | 1.19 | 28 | 1.1 | 11 (w/REN) | 2.0 | 14 | 0.8 | 7 | | | | |
| REN | — | | (pooled w/StL) | | — | | 1.5 | 7 | — | | — | |
| Osteoarthritis ("degenerative joint disease") | | | | | | | | | | | | |
| StL | 1.16 | 720 | 1.66 | 53 | 1.11 | 485 | 0.93 | 204 | | | | |
| REN | 1.23 | 58 | 1.80[2] | 61 | 1.22 | 53 | 1.14 | 72 | 0.7 | 5 | 2.9 | 10 |
| Total knee replacement | | | | | | | | | | | | |
| StL | 1.27 | 20 | 0.7 | 5 (w/REN) | 0.9 | 10 | — | | | | | |
| Hip replacement | | | | | | | | | | | | |
| StL | 1.05 | 42 | 1.5 | 6 (w/REN) | 1.13 | 25 | 2.0 | 4 (w/REN) | | | | |
| REN | 3.0 | 4 | (pooled w/StL) | | — | | (pooled w/StL) | | — | | — | |
| Degenerative disc disease | | | | | | | | | | | | |
| StL | 0.7 | 71 | 3.0 | 4 (w/REN) | 0.79 | 32 | 0.9 | 10 (w/REN) | | | | |
| Carpal tunnel syndrome | | | | | | | | | | | | |
| StL | 0.96 | 37 | 0.66 | 22 (w/REN) | 0.5 | 15 | 1.1 | 17 | | | | |
| REN | 1.1 | 11 | (pooled w/StL) | | 0.9 | 13 | 0.35[3] | 62 | — | | — | |
| Scleroderma | | | | | | | | | | | | |
| StL + REN | — | | 3.0 | 2 | — | | 4.0 | 3 | — | | — | |
| Sarcoidosis | | | | | | | | | | | | |
| StL | 1.0 | 4 | — | | 0.8 | 14 (w/REN) | 0.8 | 14 (w/REN) | | | | |

See Table 5 for abbreviations.
[1]Pooled data for men and women combined.
[2]$p < 0.05$, [3]$p < 0.005$.

Table 19. ACE *D/D* Odds Ratios (OR) of Dermatologic Diseases

| | *WM* | | *WF* | | *BM* | | *BF* | | *HM* | | *HF* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *StL* | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n | *OR* | n |
| Eczema | 0.99 | 20 | — | | 1.6 | 16 | 1.0 | 3[1] | | | | |
| Psoriasis | 1.49 | 21 | — | | 0.5 | 5 | | | | | | |

WM, white male; WF, white female; BM, black male; BF, black female; HM, Hispanic male; HF, Hispanic female.
[1]Pooled with REN.

Table 20. Number of Disease Categories for Which ACE *D/D* Is a Susceptibility [Odds Ratio (OR) ≥1.15] Versus a Protective (OR ≤0.60) Genotype

| | *WM* | *WF* | *BM* | *BF* | *HM* | *HF* |
|---|---|---|---|---|---|---|
| Number of disease categories | 219 | 78 | 196 | 132 | 14 | 13 |
| Number of diseases with | | | | | | |
| OR ≥1.15 | 157 (71.7%) | 46 (59.0%) | 79 (40.3%) | 50 (37.9%) | 9 (64.3%) | 4 (30.8%) |
| OR ≤0.60 | 8 (3.7%) | 4 (5.1%) | 4 (2.0%) | 7 (5.3%) | 3 (21.4%) | 1 (7.7%) |

WM, white male; WF, white female; BM, black male; BF, black female; HM, Hispanic male; HF, Hispanic female. Only diseases with sample sizes of at least 20 patients were considered.

Table 21. Clinical Role of ACE *D/D* Genotype Different Ethnic Groups

| *Number of diseases* | *Whites* | *Blacks* | *Hispanics* |
|---|---|---|---|
| To which *D/D* predisposes | 203 (68.4%) | 129 (39.3%) | 13 (48.1%) |
| Against which *D/D* protects | 12 (4.0%) | 11 (3.4%) | 4 (14.8%) |

Shown are the numbers of diseases with a sample size of ≥20, for which *D/D* either predisposes to, or protects from, disease. Data are from Table 20, pooling both genders.
$p < 0.001$, whites versus blacks; $p < 0.05$, blacks versus Hispanics; $p < 0.025$, whites versus Hispanics.




**FIG. 1.** Hypothetical scheme for ACE at the origin of many common diseases. AII, angiotensin II; $AT_1R$, angiotensin II type 1 receptor; $AT_2R$, angiotensin II type 2 receptor; GRKs, G-protein receptor kinases; "norepinephrine" and "dopamine" refer to the synthesis, release, transport, and reuptake proteins for these neurotransmitters; PKC, protein kinase C; Insulin R, insulin receptor, down-regulated by PKC (see White et al.[79]). The $AT_1R$ appears to be involved in vasoconstriction, interaction with catecholamines such as norepinephrine and dopamine, inhibition of the insulin receptor, and stimulation of cell proliferation, whereas the $AT_2R$ appears to mediate apoptosis through phosphatases such as mitogen-activated protein kinase phosphatase-1 (see Gallinat et al.[82]).

## REFERENCES


1. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–1346.
2. Yoneya K, Okamoto H, Machida M, Onozuka H, Noguchi M, Mikami T, Kawaguchi H, Murakami M, Uede T, Kitabatake A: Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1995;130: 1089–1093.
3. Lechin M, Quinones MA, Omran A, Hill R, Yu QT, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian A: Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995;92:1808–1812.
4. Prasad N, O'Kane KP, Johnstone HA, Wheeldon NM, McMahon AD, Webb DJ, MacDonald TM: The relationship between blood pressure and left ventricular mass in essential hypertension is observed only in the presence of the angiotensin-converting enzyme gene deletion allele. Q J Med 1994;87:659–662.
5. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M: DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994;90:2622–2628.
6. Schunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, Lorell BH, Riegger GA: Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994;330:1634–1638.
7. Marian AJ, Yu QT, Workman R, Greve G, Roberts R: Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993;342:1085–1086.
8. Lindpaintner K, Lee M, Larson MG, Rao VS, Pfeffer MA, Ordovas JM, Schaefer EJ, Wilson AF, Wilson PW, Vasan RS, Myers RH, Levy D: Absence of an association or genetic linkage between the angiotensin-converting enzyme gene and left ventricular mass. N Engl J Med 1996;334:1023–1028.
9. Wong KK, Summers KM, Burstow DJ, West MJ: Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction. Clin Exp Pharmacol Physiol 1995;22:438–440.
10. Kupari M, Perola M, Koskinen P, Virolainen J, Karhunen PJ: Left ventricular size, mass, and function in relation to angiotensin-converting enzyme gene polymorphism in humans. Am J Physiol 1994;267: H1107–H1111.
11. Harn HJ, Chang CY, Ho LI, Liu CA, Jeng JR, Lin FG, Jent-Wei: Evidence that polymorphism of the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in the Chinese population. Biochem Mol Biol Int 1995;35:1175–1181.
12. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB: Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993;342:1073–1075.
13. Duru K, Farrow S, Wang JM, Lockette W, Kurtz T: Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension. Am J Hypertens 1994;7:759–762.
14. Bloem LJ, Manatunga AK, Pratt JH: Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996;27: 62–66.
15. Arbustini E, Grasso M, Fasani R, Klersy C, Diegoli M, Porcu E, Banchieri N, Fortina P, Danesino C, Specchia G: Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J 1995;74:584–591.
16. Castellano M, Muiesan ML, Rizzoni D, Beschi M, Pasini G, Cinelli A, Salvetti M, Porteri E, Bettoni G, Kreutz R, Lindpaintner K, Rosei EA: Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. Circulation 1995;91:2721–2724.
17. Ishigami T, Iwamoto T, Tamura K, Yamaguchi S, Iwasawa K, Uchino K, Umemura S, Ishii M: Angiotensin I converting enzyme (ACE) gene polymorphism and essential hypertension in Japan. Ethnic difference of ACE genotype. Am J Hypertens 1995;8:95–97.
18. Gu XX, Spaepen M, Guo C, Fagard R, Amery A, Lijnen P, Cassiman JJ: Lack of association between the I/D polymorphism of the angiotensin-converting enzyme gene and essential hypertension in a Belgian population. J Hum Hypertens 1994;8:683–685.
19. Morris BJ, Zee RY, Schrader AP: Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals. J Clin Invest 1994;94: 1085–1089.
20. Berge KE, Berg K: No effect of insertion/deletion polymorphism at the ACE locus on normal blood pressure level or variability. Clin Genet 1994;45: 169–174.
21. Summers KM, West JA, Huggard PR, West MJ: Angiotensin-converting enzyme and regulation of blood pressure in a large Australian family. Clin Exp Pharmacol Physiol 1993;20:320–323.
22. Schmidt S, Van Hooft IM, Grobbee DE, Ganten D, Ritz E: Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study. J Hypertens 1993;11:345–348.
23. Higashimori K, Zhao Y, Higaki J, Kamitani A, Katsuya T, Nakura J, Miki T, Mikami H, Ogihara T: Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun 1993;191:399–404.
24. Zee RY, Lou YK, Griffiths LR, Morris BJ: Association

of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992;184:9–15.
25. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel J-M: Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1992;1:72–75.
26. Ohishi M, Fujii K, Minamino T, Higaki J, Kamitani A, Rakugi H, Zhao Y, Mikami H, Miki T, Ogihara T: A potent genetic risk factor for restenosis. Nat Genet 1993; 5:324–325.
27. van Bockxmeer FM, Mamotte CD, Gibbons FA, Burke V, Taylor RR: Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation 1995;92:2066–2071.
28. Hamon M, Bauters C, Amant C, McFadden EP, Helbecque N, Lablanche JM, Bertrand ME, Amouyel P: Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995;92:296–299.
29. Samani NJ, Martin DS, Brack M, Cullen J, Wallis R, Lodwick D, Chauhan A, Harley A, Thompson JR, Gershlick AH, de Bono DP: Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet 1995;345:1013–1016.
30. Gardemann A, Weiss T, Schwartz O, Eberbach A, Katz N, Hehrlein FW, Tillmanns H, Waas W, Haberbosch W: Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. Circulation 1995;92:2796–2799.
31. Schuster H, Wienker TF, Stremmler U, Noll B, Steinmetz A, Luft FC: An angiotensin-converting enzyme gene variant is associated with acute myocardial infarction in women but not in men. Am J Cardiol 1995;76:601–603.
32. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel JM, Ward RH: Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 1995;91:2120–2124.
33. Leatham E, Barley J, Redwood S, Hussein W, Carter N, Jeffery S, Bath PM, Camm A: Angiotensin-1 converting enzyme (ACE) polymorphism in patients presenting with myocardial infarction or unstable angina. J Hum Hypertens 1994;8:635–638.
34. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641–644.
35. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH: A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706–711.
36. Takahashi K, Nakamura H, Kubota I, Takahashi N, Tomoike H: Association of ACE gene polymorphisms with coronary artery disease in a northern area of Japan. Jpn Heart J 1995;36:557–564.
37. Wang XL, McCredie RM, Wilcken DE: Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:115–119.
38. Perola M, Sajantila A, Sarti C, Stengard J, Tamminen M, Puska P, Huttunen J, Tuomilehto J, Peltonen L: Angiotensin-converting enzyme genotypes in the high- and low-risk area for coronary heart disease in Finland. Genet Epidemiol 1995;12:391–399.
39. Beohar N, Damaraju S, Prather A, Yu QT, Raizner A, Kleiman NS, Roberts R, Marian AJ: Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Invest Med 1995;43:275–280.
40. Nakai K, Itoh C, Miura Y, Nakai K, Syo T, Musya T, Hiramori K: Deletion polymorphism of the angiotensin I-converting enzyme gene associates with increased risk for ischemic heart diseases in the Japanese. Rinsho Byori 1995;43:347–352.
41. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M: A DNA variant at the angiotensin converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 1995;91:270–274.
42. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, Miyakawa T, Iwasaki R, Hiramori K: Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994;90:2199–2202.
43. Friedl W, Krempler F, Paulweber B, Pichler M, Sandhofer F: A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population. Atherosclerosis 1995;112:137–143.
44. Miettinen HE, Korpela K, Hamalainen L, Kontula K: Polymorphisms of the apolipoprotein and angiotensin converting enzyme genes in young North Karelian patients with coronary heart disease. Hum Genet 1994;94:189–192.
45. Zingone A, Dominijanni A, Mele E, Marasco O, Melina F, Minchella P, Quaresima B, Tiano MT, Gnasso A, Pujia A, Perrotti N: Deletion polymorphism in the gene for angiotensin converting enzyme is associated with elevated fasting blood glucose levels. Hum Genet 1994;94:207–209.
46. Panahloo A, Andres C, Mohamed Ali V, Gould M, Panahloo A, Haines AP, Humphries S, Talmud P: The insertion allele of the ACE gene I/D polymorphism. A candidate gene for insulin resistance? Circulation 1995;92:3390–3393.
47. Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994;43:690–695.

48. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH: Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995;44:489–494.
49. Ohno T, Kawazu S, Tomono S: Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism 1996;45:218–222.
50. Dudley CR, Keavney B, Stratton IM, Turner RC, Ratcliffe PJ: U.K. Prospective Diabetes Study. XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney Int 1995;48:1907–1911.
51. Strojek K, Grzeszczak W, Rudzki H, Pokrzywnicki W, Lacka B, Schmidt S, Ritz E: Does an association between angiotensin I converting enzyme gene polymorphism and the prevalence of diabetic nephropathy in patients with diabetes type II exist? Pol Arch Lmed Wewn 1995;94:214–218.
52. Panagiotopoulos S, Smith TJ, Aldred GP, Baker EJ, Jacklin CJ, Jerums G: Angiotensin-converting enzyme (ACE) gene polymorphism in type II diabetic patients with increased albumin excretion rate. J Diabetes Complications 1995;9:272–276.
53. Fujisawa T, Ikegami H, Shen GQ, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J: Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995;18:983–985.
54. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384–388.
55. Nagi DK, Mansfield MW, Stickland MH, Grant PJ: Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM. Diabet Med 1995;12:997–1001.
56. Pujia A, Gnasso A, Irace C, Dominijanni A, Zingone A, Perrotti N, Colonna A, Mattioli PL: Association between ACE-D/D polymorphism and hypertension in type II diabetic subjects. J Hum Hypertens 1994;8: 687–691.
57. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Boelskifte S, Borch-Johnsen K: Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 1995;38:798–803.
58. Ruiz J, Blanche H, Cohen N, Velho G, Cambien F, Cohen D, Passa P, Froguel P: Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994;91:3662–3665.
59. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347:94–95.
60. Yorioka T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M: Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 1995;44:80–85.
61. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162–2169.
62. Arbustini E, Grasso M, Leo G, Tinelli C, Fasani R, Diegoli M, Banchieri N, Cipriani A, Gorrini M, Semenzato G, Luisetti M: Polymorphism of angiotensin-converting enzyme gene in sarcoidosis. Am J Respir Crit Care Med 1996;153:851–854.
63. Bonithon Kopp C, Ducimetiere P, Touboul PJ, Feve JM, Billaud E, Courbon D, Heraud V: Plasma angiotensin-converting enzyme activity and carotid wall thickening. Circulation 1994;89:952–954.
64. Sharma P, Carter ND, Barley J, Lunt R, Seymour CA, Brown MM: Polymorphisms in the gene encoding angiotensin 1-converting enzyme and relationship to its post-translational product in cerebral infarction. J Hum Hypertens 1994;8:633–634.
65. Schachter F, Faure Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D: Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29–32.
66. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat Genet 2001;29:306–309.
67. Moskowitz DW: The human gene pool: limits to human health. In: von Pfusterschmid-Hardenstein H, ed. Das normale und das pathologische—was ist gesund? Europaisches Forum Alpbach 1996. Vienna: Ibera Verlag, 1997:50–70, 680–681.
68. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1, dipeptidyl carboxypeptidase I). Nucleic Acids Res 1992;20:1433.
69. Fogarty DG, Maxwell AP, Doherty CC, Hughes AE, Nevin NC: ACE gene typing. Lancet 1994;343:851.
70. Rutledge DR, Browe CS, Ross EA: Frequencies of the angiotensinogen gene and angiotensin I converting enzyme (ACE) gene polymorphisms in African Americans. Biochem Mol Biol Int 1994;34:1271–1275.
71. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffery S, Ogunlesi AO, Sagnella GA: Angiotensin converting enzyme insertion/deletion polymorphism: association with ethnic origin. J Hypertens 1994;12:955–957.
72. Reed TE: Caucasian genes in American Negroes. Science 1969;165:762–768.
73. Adams J, Ward RH: Admixture studies and the detection of selection. Science 1973;180:1137–1143.

74. Chakraborty R, Kamboh MI, Nwankwo M, Ferrell RE: Caucasian genes in American blacks: new data. Am J Hum Genet 1992;50:145–155.
75. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H: Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387–1388.
76. Kojima S, Inenaga T, Matsuoka H, Kuramochi M, Omae T, Nara Y, Yamori Y: The association between salt sensitivity of blood pressure and some polymorphic factors. J Hypertens 1994;12:797–801.
77. Dzau VJ, Gibbons GH, Morishita R, Pratt RE: New perspectives in hypertension research: potentials of vascular biology. Hypertension 1994;23:1132–1140.
78. Greenberg DA, Doneshka P: Partitioned association-linkage test: distinguishing 'necessary' from 'susceptibility' loci. Genet Epidemiol 1996;13:243–252.
79. White MF, Stegmann EW, Dull TJ, Ullrich A, Kahn CR: Characterization of an endogenous substrate of the insulin receptor in cultured cells. J Biol Chem 1987;262:9769–9777.
80. Moskowitz DW: From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Ther 2002;4:519–531.
81. Rieder MJ, Taylor SL, Clark AG, Nickerson DA: Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999;22:59–62.
82. Gallinat S, Busche S, Raizada MK, Sumners C: The angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol Endocrinol Metab 2000;278:E357–E374.

Address reprint requests to:
*David W. Moskowitz, M.D., M.A. (Oxon.), F.A.C.P.*
*Chairman and Chief Medical Officer*
*GenoMed, Inc.*
*4560 Clayton Avenue*
*St. Louis, MO 63110*

*E-mail:* dwmoskowitz@genomedics.com

**This article has been cited by:**


1. Neil S Ryder. 2008. Discontinued drugs in 2006: anti-infectives. *Expert Opinion on Investigational Drugs* **16**:12, 1867-1878. [CrossRef]
2. Undurti N. Das. 2006. Essential fatty acids: biochemistry, physiology and pathology. *Biotechnology Journal* **1**:4, 420-439. [CrossRef]
3. D. W. Moskowitz . 2003. Pathophysiologic Implications of Angiotensin I-Converting Enzyme as a Mechanosensor: DiabetesPathophysiologic Implications of Angiotensin I-Converting Enzyme as a Mechanosensor: Diabetes. *Diabetes Technology Therapeutics* **5**:2, 189-199. [Abstract] [PDF] [PDF Plus]
4. David W. Moskowitz . 2002. Is "Somatic" Angiotensin I-Converting Enzyme a Mechanosensor?Is "Somatic" Angiotensin I-Converting Enzyme a Mechanosensor?. *Diabetes Technology Therapeutics* **4**:6, 841-858. [Abstract] [PDF] [PDF Plus]